How Non-Opioid Pain Drugs Work: NaV1.8 Blockers Explained

A Quarter-Century Without a New Painkiller

For 25 years, doctors treating moderate to severe acute pain had essentially one powerful option: opioids. The last genuinely novel oral painkiller approved by the U.S. Food and Drug Administration was celecoxib, a COX-2 inhibitor, back in 1998. Everything that followed was either a reformulation or a variation on the same opioid theme.

That changed in January 2025 when the FDA approved suzetrigine (brand name Journavx), a drug developed by Vertex Pharmaceuticals. It belongs to an entirely new class — selective sodium channel blockers targeting a receptor called NaV1.8 — and it works in a fundamentally different way from anything that came before it.

Why Opioids Are Such a Double-Edged Sword

To understand why suzetrigine matters, it helps to understand what opioids actually do. Opioids work by binding to mu (μ) opioid receptors scattered throughout the nervous system — in the spinal cord, the gut, and, crucially, the brain's reward centers. That is precisely why they are so effective at killing pain: they suppress pain signals at multiple levels simultaneously.

But flooding the brain's reward circuitry with opioid signals is also what makes these drugs dangerously addictive. According to the World Health Organization, opioids cause more than 120,000 deaths worldwide every year. In the United States alone, the CDC recorded nearly 87,000 drug overdose deaths in the 12 months ending September 2024, with synthetic opioids involved in the vast majority of cases.

The clinical dilemma has always been stark: withhold opioids and leave patients in agony, or prescribe them and risk addiction, respiratory depression, and overdose. A drug that could sidestep that trade-off entirely would be transformative.

What Is NaV1.8 and Why Does It Matter?

Pain signals do not simply appear in the brain — they travel there. When tissue is damaged, specialized nerve cells called nociceptors (pain-sensing neurons) fire electrical impulses that race along peripheral nerves toward the spinal cord and brain. Those impulses depend on voltage-gated sodium channels — proteins in the nerve cell membrane that open briefly to let sodium ions flood in, generating the electrical spike.

There are multiple subtypes of these channels (NaV1.1 through NaV1.9), distributed throughout the body and brain. The key insight behind suzetrigine is that NaV1.8 is expressed almost exclusively in peripheral pain-sensing neurons — it is not found in the brain or the heart in meaningful quantities. Block NaV1.8 and you cut the pain signal before it ever reaches the central nervous system, without touching any of the brain circuits that drive addiction or sedation.

According to peer-reviewed research published in PMC (NIH), suzetrigine binds to the second voltage-sensing domain (VSD2) of NaV1.8 and locks the channel in a closed state, preventing the sodium influx that would normally carry the pain signal forward. Its selectivity is exceptional: it inhibits NaV1.8 at concentrations more than 30,000 times lower than those needed to affect other sodium channel subtypes.

What the Clinical Trials Showed

Vertex tested suzetrigine in two large Phase 3 randomized trials involving adults with moderate to severe acute postoperative pain. Results showed significant reductions in pain intensity compared with placebo, with a median onset of relief within two hours. In head-to-head comparisons with hydrocodone/acetaminophen (a standard opioid combination), suzetrigine performed comparably for pain relief but with fewer side effects and no addictive potential, as confirmed by the FDA's approval announcement.

Critically, suzetrigine showed no respiratory depression — the mechanism behind opioid overdose deaths — and no sedation or euphoria, which are hallmarks of opioid use disorder risk.

What It Cannot Do — Yet

Suzetrigine is currently approved only for acute pain — the kind experienced after surgery or injury. It is not yet approved for chronic pain conditions such as neuropathy or arthritis, though clinical trials are ongoing. As Yale Medicine notes, the drug also carries a higher price tag than generic opioids, which could limit access in some healthcare systems.

Researchers are also investigating whether similar NaV1.8-targeting drugs — or blockers of related channels like NaV1.7 — could one day address chronic pain, the far larger and harder-to-treat category that affects hundreds of millions of people globally.

A New Pharmacological Frontier

The approval of suzetrigine represents more than just one new drug. It validates ion channel selectivity as a viable strategy for pain management — a concept that pharmaceutical scientists had pursued for decades without a clinical breakthrough. It also demonstrates that the peripheral nervous system can be targeted precisely enough to control pain without the systemic risks that have made opioids so destructive.

Whether suzetrigine itself becomes a first-line standard of care, or whether it is the prototype for a broader family of safer analgesics, the principle it proves is the same: you do not need to reach into the brain to stop the pain.